A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors

Inigo Espinosa, Cheng Han Lee, Mi Kyung Kim, Bich Tien Rouse, Subbaya Subramanian, Kelli Montgomery, Sushama Varma, Christopher Corless, Michael Heinrich, Kevin S. Smith, Zhong Wang, Brian Rubin, Torsten O. Nielsen, Robert S. Seitz, Douglas T. Ross, Robert B. West, Michael L. Cleary, Matt Van De Rijn

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GIST) occur primarily in the wall of the intestine and are characterized by activating mutations in the receptor tyrosine kinases genes KIT or PDGFRA. The diagnosis of GIST relies heavily on the demonstration of KIT/CD117 protein expression by immunohistochemistry. However, KIT expression is absent in ∼4% to 15% of GIST and this can complicate the diagnosis of GIST in patients who may benefit from treatment with receptor tyrosine kinase inhibitors. We previously identified DOG1/TMEM16A as a novel marker for GIST using a conventional rabbit antipeptide antiserum and an in situ hybridization probe. Here, we describe 2 new monoclonal antibodies against DOG1 (DOG1.1 and DOG1.3) and compare their staining profiles with KIT and CD34 antibodies on 447 cases of GIST. These included 306 cases with known mutational status for KIT and PDGFRA from a molecular consultation service. In addition, 935 other mesenchymal tumors and 432 nonsarcomatous tumors were studied. Both DOG1 antibodies showed high sensitivity and specificity for GIST, with DOG1.1 showing some advantages. This antibody yielded positive staining in 370 of 425 (87%) scorable GIST, whereas CD117 was positive in 317 of 428 (74%) GIST and CD34 in 254 of 430 (59%) GIST. In GIST with mutations in PDGFRA, 79% (23/29) showed DOG1.1 immunoreactivity while only 9% (3/32) and 27% (9/33) stained for CD117 and CD34, respectively. Only 1 of 326 (0.3%) leiomyosarcomas and 1 of 39 (2.5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT.

Original languageEnglish (US)
Pages (from-to)210-218
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume32
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Gastrointestinal Stromal Tumors
Monoclonal Antibodies
Receptor Protein-Tyrosine Kinases
Antibodies
Staining and Labeling
Synovial Sarcoma
Neoplasms
Seminoma
Mutation
Leiomyosarcoma
Intestines
In Situ Hybridization
Immune Sera
Melanoma
Referral and Consultation
Immunohistochemistry
Rabbits
Carcinoma

Keywords

  • DOG1
  • GIST
  • Immunohistochemistry
  • Monoclonal antibody

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Espinosa, I., Lee, C. H., Kim, M. K., Rouse, B. T., Subramanian, S., Montgomery, K., ... Van De Rijn, M. (2008). A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. American Journal of Surgical Pathology, 32(2), 210-218. https://doi.org/10.1097/PAS.0b013e3181238cec

A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. / Espinosa, Inigo; Lee, Cheng Han; Kim, Mi Kyung; Rouse, Bich Tien; Subramanian, Subbaya; Montgomery, Kelli; Varma, Sushama; Corless, Christopher; Heinrich, Michael; Smith, Kevin S.; Wang, Zhong; Rubin, Brian; Nielsen, Torsten O.; Seitz, Robert S.; Ross, Douglas T.; West, Robert B.; Cleary, Michael L.; Van De Rijn, Matt.

In: American Journal of Surgical Pathology, Vol. 32, No. 2, 02.2008, p. 210-218.

Research output: Contribution to journalArticle

Espinosa, I, Lee, CH, Kim, MK, Rouse, BT, Subramanian, S, Montgomery, K, Varma, S, Corless, C, Heinrich, M, Smith, KS, Wang, Z, Rubin, B, Nielsen, TO, Seitz, RS, Ross, DT, West, RB, Cleary, ML & Van De Rijn, M 2008, 'A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors', American Journal of Surgical Pathology, vol. 32, no. 2, pp. 210-218. https://doi.org/10.1097/PAS.0b013e3181238cec
Espinosa, Inigo ; Lee, Cheng Han ; Kim, Mi Kyung ; Rouse, Bich Tien ; Subramanian, Subbaya ; Montgomery, Kelli ; Varma, Sushama ; Corless, Christopher ; Heinrich, Michael ; Smith, Kevin S. ; Wang, Zhong ; Rubin, Brian ; Nielsen, Torsten O. ; Seitz, Robert S. ; Ross, Douglas T. ; West, Robert B. ; Cleary, Michael L. ; Van De Rijn, Matt. / A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. In: American Journal of Surgical Pathology. 2008 ; Vol. 32, No. 2. pp. 210-218.
@article{804529009e3845f1a36936539ca680fd,
title = "A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors",
abstract = "Gastrointestinal stromal tumors (GIST) occur primarily in the wall of the intestine and are characterized by activating mutations in the receptor tyrosine kinases genes KIT or PDGFRA. The diagnosis of GIST relies heavily on the demonstration of KIT/CD117 protein expression by immunohistochemistry. However, KIT expression is absent in ∼4{\%} to 15{\%} of GIST and this can complicate the diagnosis of GIST in patients who may benefit from treatment with receptor tyrosine kinase inhibitors. We previously identified DOG1/TMEM16A as a novel marker for GIST using a conventional rabbit antipeptide antiserum and an in situ hybridization probe. Here, we describe 2 new monoclonal antibodies against DOG1 (DOG1.1 and DOG1.3) and compare their staining profiles with KIT and CD34 antibodies on 447 cases of GIST. These included 306 cases with known mutational status for KIT and PDGFRA from a molecular consultation service. In addition, 935 other mesenchymal tumors and 432 nonsarcomatous tumors were studied. Both DOG1 antibodies showed high sensitivity and specificity for GIST, with DOG1.1 showing some advantages. This antibody yielded positive staining in 370 of 425 (87{\%}) scorable GIST, whereas CD117 was positive in 317 of 428 (74{\%}) GIST and CD34 in 254 of 430 (59{\%}) GIST. In GIST with mutations in PDGFRA, 79{\%} (23/29) showed DOG1.1 immunoreactivity while only 9{\%} (3/32) and 27{\%} (9/33) stained for CD117 and CD34, respectively. Only 1 of 326 (0.3{\%}) leiomyosarcomas and 1 of 39 (2.5{\%}) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT.",
keywords = "DOG1, GIST, Immunohistochemistry, Monoclonal antibody",
author = "Inigo Espinosa and Lee, {Cheng Han} and Kim, {Mi Kyung} and Rouse, {Bich Tien} and Subbaya Subramanian and Kelli Montgomery and Sushama Varma and Christopher Corless and Michael Heinrich and Smith, {Kevin S.} and Zhong Wang and Brian Rubin and Nielsen, {Torsten O.} and Seitz, {Robert S.} and Ross, {Douglas T.} and West, {Robert B.} and Cleary, {Michael L.} and {Van De Rijn}, Matt",
year = "2008",
month = "2",
doi = "10.1097/PAS.0b013e3181238cec",
language = "English (US)",
volume = "32",
pages = "210--218",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors

AU - Espinosa, Inigo

AU - Lee, Cheng Han

AU - Kim, Mi Kyung

AU - Rouse, Bich Tien

AU - Subramanian, Subbaya

AU - Montgomery, Kelli

AU - Varma, Sushama

AU - Corless, Christopher

AU - Heinrich, Michael

AU - Smith, Kevin S.

AU - Wang, Zhong

AU - Rubin, Brian

AU - Nielsen, Torsten O.

AU - Seitz, Robert S.

AU - Ross, Douglas T.

AU - West, Robert B.

AU - Cleary, Michael L.

AU - Van De Rijn, Matt

PY - 2008/2

Y1 - 2008/2

N2 - Gastrointestinal stromal tumors (GIST) occur primarily in the wall of the intestine and are characterized by activating mutations in the receptor tyrosine kinases genes KIT or PDGFRA. The diagnosis of GIST relies heavily on the demonstration of KIT/CD117 protein expression by immunohistochemistry. However, KIT expression is absent in ∼4% to 15% of GIST and this can complicate the diagnosis of GIST in patients who may benefit from treatment with receptor tyrosine kinase inhibitors. We previously identified DOG1/TMEM16A as a novel marker for GIST using a conventional rabbit antipeptide antiserum and an in situ hybridization probe. Here, we describe 2 new monoclonal antibodies against DOG1 (DOG1.1 and DOG1.3) and compare their staining profiles with KIT and CD34 antibodies on 447 cases of GIST. These included 306 cases with known mutational status for KIT and PDGFRA from a molecular consultation service. In addition, 935 other mesenchymal tumors and 432 nonsarcomatous tumors were studied. Both DOG1 antibodies showed high sensitivity and specificity for GIST, with DOG1.1 showing some advantages. This antibody yielded positive staining in 370 of 425 (87%) scorable GIST, whereas CD117 was positive in 317 of 428 (74%) GIST and CD34 in 254 of 430 (59%) GIST. In GIST with mutations in PDGFRA, 79% (23/29) showed DOG1.1 immunoreactivity while only 9% (3/32) and 27% (9/33) stained for CD117 and CD34, respectively. Only 1 of 326 (0.3%) leiomyosarcomas and 1 of 39 (2.5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT.

AB - Gastrointestinal stromal tumors (GIST) occur primarily in the wall of the intestine and are characterized by activating mutations in the receptor tyrosine kinases genes KIT or PDGFRA. The diagnosis of GIST relies heavily on the demonstration of KIT/CD117 protein expression by immunohistochemistry. However, KIT expression is absent in ∼4% to 15% of GIST and this can complicate the diagnosis of GIST in patients who may benefit from treatment with receptor tyrosine kinase inhibitors. We previously identified DOG1/TMEM16A as a novel marker for GIST using a conventional rabbit antipeptide antiserum and an in situ hybridization probe. Here, we describe 2 new monoclonal antibodies against DOG1 (DOG1.1 and DOG1.3) and compare their staining profiles with KIT and CD34 antibodies on 447 cases of GIST. These included 306 cases with known mutational status for KIT and PDGFRA from a molecular consultation service. In addition, 935 other mesenchymal tumors and 432 nonsarcomatous tumors were studied. Both DOG1 antibodies showed high sensitivity and specificity for GIST, with DOG1.1 showing some advantages. This antibody yielded positive staining in 370 of 425 (87%) scorable GIST, whereas CD117 was positive in 317 of 428 (74%) GIST and CD34 in 254 of 430 (59%) GIST. In GIST with mutations in PDGFRA, 79% (23/29) showed DOG1.1 immunoreactivity while only 9% (3/32) and 27% (9/33) stained for CD117 and CD34, respectively. Only 1 of 326 (0.3%) leiomyosarcomas and 1 of 39 (2.5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT.

KW - DOG1

KW - GIST

KW - Immunohistochemistry

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=38649098794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649098794&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3181238cec

DO - 10.1097/PAS.0b013e3181238cec

M3 - Article

C2 - 18223323

AN - SCOPUS:38649098794

VL - 32

SP - 210

EP - 218

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 2

ER -